Q3 EPS Estimates for Nuvectis Pharma Decreased by Analyst

Key Points

• Roth Capital has lowered its earnings per share estimate for Nuvectis Pharma, projecting a loss of ($0.22) for Q3 2025, down from a previous estimate of ($0.20).
• Nuvectis Pharma recently reported a Q2 earnings loss of ($0.30) per share, missing analysts' expectations by ($0.05).
• Despite declining earnings forecasts, the company has seen significant institutional investment, with over 96% of its shares owned by institutional investors and hedge funds.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Stock analysts at Roth Capital lowered their Q3 2025 EPS estimates for shares of Nuvectis Pharma in a report issued on Tuesday, August 5th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($0.22) per share for the quarter, down from their prior estimate of ($0.20). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at $2.43 EPS and FY2029 earnings at $3.37 EPS.

Several other equities analysts have also recently issued reports on NVCT. HC Wainwright lowered their target price on shares of Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, August 4th. Wall Street Zen cut shares of Nuvectis Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, June 29th.

Nuvectis Pharma Stock Performance

Shares of NASDAQ NVCT traded up $0.09 during mid-day trading on Thursday, hitting $6.09. The stock had a trading volume of 71,078 shares, compared to its average volume of 146,735. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $11.80. The business has a 50 day moving average price of $7.90 and a two-hundred day moving average price of $8.27. The firm has a market cap of $155.08 million, a P/E ratio of -5.21 and a beta of -0.26.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05).

Insider Buying and Selling at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri bought 5,603 shares of the business's stock in a transaction on Friday, June 20th. The shares were bought at an average price of $7.99 per share, for a total transaction of $44,767.97. Following the completion of the purchase, the insider directly owned 2,981,806 shares of the company's stock, valued at approximately $23,824,629.94. This trade represents a 0.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 39,045 shares of company stock valued at $314,300 in the last ninety days. Insiders own 30.52% of the company's stock.

Institutional Investors Weigh In On Nuvectis Pharma

A number of large investors have recently modified their holdings of the business. Baldwin Wealth Partners LLC MA boosted its position in Nuvectis Pharma by 0.7% in the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock valued at $3,502,000 after buying an additional 2,500 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Nuvectis Pharma by 110.8% during the 2nd quarter. Geode Capital Management LLC now owns 285,332 shares of the company's stock worth $2,132,000 after purchasing an additional 149,999 shares during the period. Iridian Asset Management LLC CT acquired a new position in Nuvectis Pharma during the 1st quarter worth about $2,481,000. Marshall Wace LLP raised its position in Nuvectis Pharma by 191.0% in the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock valued at $674,000 after purchasing an additional 81,757 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Nuvectis Pharma in the 1st quarter valued at about $446,000. Hedge funds and other institutional investors own 96.77% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.